Table 1.
Overview of the literature on the (significant) relation between biomarker and radiographic progression
| Author | Population | No. | Biomarker | Classification | Results |
|---|---|---|---|---|---|
| Syversen et al.10 | RA ≤4 yr | 136 | C2C (baseline serum) | SHS rapid >1 vs. slow <1 | NS |
| (radiographic progression per yr, progression change baseline to 5 or 10 yr) | |||||
| Mullan et al.9 | RA | 45 | C2C (baseline,1, 3, 6, 9,12-mo serum) | C2C ↑ at 1, 3 mo | |
| PsA | 17 | C1,2C | SHS rapid >1.5 vs. slow <1.5 | C1,2C ↑ at 1, 3 mo | |
| (mean 11 yr, DAS28 >3.2) | CPII | (radiographic progression at 1 yr) | NS | ||
| ΔCOL (ΔC2C + ΔC1,2C + ΔCPII) | ΔCOL ↑ at 1, 3, 6, 9 mo | ||||
| Verstappen et al.11 | RA ≤1 yr | 87 | C2C (1, 2, 3, 4-yr serum) | C2C ↑ | |
| C1,2C | 66 th = SHS >7.4 vs. 33 rd percentile = SHS <2.3 | C1,2C ↑ | |||
| CS846 | (radiographic progression over 4-yr span) | CS846 ↑ | |||
| CPII | NS | ||||
| Ishiguro et al.7 | RA | 63 | C2C (knee SF) | Mild vs. moderate vs. severe RA | NS |
| (mean 10 yr) | CS846 | Mild vs. moderate RA | CS846 ↓ | ||
| CPII | Mild vs. moderate vs. severe RA | NS | |||
| (Larsen score: 0, 1 = mild; 2, 3 = moderate; 4, 5 = severe) | |||||
| Mansson et al.8 | RA ≤2 yr | 18 | CS846 (baseline serum) | Rapid vs. slow hip-joint radiographic progression | CS846 ↓ |
| CPII | (Larsen score: rapid = 46; slow = 4 at 2 yr) | NS |
Number, number of patients investigated in the studies; DAS28, disease activity score based on 28 joints; mo, month; NS, not significant. PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF, synovial fluid; SHS, SharpvanderHeijde score; yr, year.